SLC5A2 and Hypoalbuminemia: Although no apparent treatment-associated physical changes, mortality, body weight change, hypoproteinemia, or hypoalbuminemia were observed in treated mice (Figure S4), laboratory examination revealed that a maximum dose of 30 mg/kg/day of SGLT2-ASOs induced very severe liver damage, as indicated by increased blood levels of liver enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT) (AST and ALT >2,000 IU/L; Figures 3A and 3B).